Stifel Maintains Buy on Dyne Therapeutics, Raises Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis maintains a Buy rating on Dyne Therapeutics (NASDAQ:DYN) and raises the price target from $35 to $41, indicating a positive outlook on the company's stock.
March 06, 2024 | 3:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Paul Matteis maintains a Buy rating on Dyne Therapeutics and raises the price target from $35 to $41.
The increase in the price target by a reputable analyst suggests a strong confidence in Dyne Therapeutics' future performance, likely leading to positive investor sentiment and a potential increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100